SCHEMBL8939945

SCHEMBL8939945

CC1(C)Cc2c(Cl)c(N)cc(C(=O)O)c2O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.41
POLB P06746 3/20 0.36
PTGES O14684 7/20 0.35
PKM P14618 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KMT2A Q03164 3/20 0.33
KDM4E B2RXH2 3/20 0.33
GFER P55789 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MEN1 O00255 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
USP2 O75604 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
APEX1 P27695 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
MCL1 Q07820 1/20 0.33
FFAR4 Q5NUL3 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042504 0.83 PTGES (0.37) POLBPTGESPKMNPSR1KMT2A
SCHEMBL8126374 0.79 PARP1 (0.40) CYP3A4POLBPTGESPKMNPSR1
SCHEMBL8940068 0.79 GPR35 (0.35) CYP3A4POLBPTGESTDP1MAPT
SCHEMBL11956874 0.76 PARP1 (0.37) CYP3A4POLBPKMNPSR1KMT2A
SCHEMBL8940038 0.75 TPMT (0.39) POLBPTGESKMT2AKDM4EMEN1
SCHEMBL8939989 0.75 PTGES (0.39) CYP3A4POLBPTGESPKMNPSR1
SCHEMBL5521738 0.74 KMT2A (0.33) CYP3A4PTGESPKMNPSR1KMT2A
SCHEMBL8500114 0.72 HTR4 (0.40) POLB
SCHEMBL2432528 0.72 FFAR4 (0.49) POLBPKMNPSR1MAPTFFAR4
Hydrochloric Acid SCHEMBL7626508 0.71 FFAR4 (0.48) POLBPKMNPSR1MAPTFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5563148-A BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS ELI LILLY AND COMPANY (US) 1996-10-08 US disclosed
EP-0307172-B1 Improvements in or relating to specific 5-HT3 antagonists LILLY CO ELI (US) 1995-10-11 EP disclosed
US-5442078-A Intermediates for specific 5-HT3 antagonists ELI LILLY AND COMPANY (US) 1995-08-15 US disclosed
US-5364863-A Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders ELI LILLY AND COMPANY (US) 1994-11-15 US disclosed
CN-1020102-C Process for producing bicyclic carboxylic acid ester and bicyclic carboxamide EIL LILLY & CO (US) 1993-03-17 CN disclosed
US-4997956-A Analgesics ELI LILLY AND COMPANY (US) 1991-03-05 US disclosed
US-4921982-A 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists ELI LILLY AND COMPANY (US) 1990-05-01 US disclosed
CN-1031841-A The improvement of special 5-HT3 antagonist LILLY CO ELI (US) 1989-03-22 CN disclosed
EP-0307172-A2 Improvements in or relating to specific 5-HT3 antagonists ELI LILLY AND COMPANY (US) 1989-03-15 EP disclosed